These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

377 related items for PubMed ID: 11223861

  • 1. Adenosine deaminase: functional implications and different classes of inhibitors.
    Cristalli G, Costanzi S, Lambertucci C, Lupidi G, Vittori S, Volpini R, Camaioni E.
    Med Res Rev; 2001 Mar; 21(2):105-28. PubMed ID: 11223861
    [Abstract] [Full Text] [Related]

  • 2. T lymphocyte ontogeny in adenosine deaminase-deficient severe combined immune deficiency after treatment with polyethylene glycol-modified adenosine deaminase.
    Weinberg K, Hershfield MS, Bastian J, Kohn D, Sender L, Parkman R, Lenarsky C.
    J Clin Invest; 1993 Aug; 92(2):596-602. PubMed ID: 8349799
    [Abstract] [Full Text] [Related]

  • 3. Development of gene therapy for immunodeficiency: adenosine deaminase deficiency.
    Blaese RM.
    Pediatr Res; 1993 Jan; 33(1 Suppl):S49-53; discussion S53-5. PubMed ID: 8433875
    [Abstract] [Full Text] [Related]

  • 4. Enzyme replacement therapy with polyethylene glycol-adenosine deaminase in adenosine deaminase deficiency: overview and case reports of three patients, including two now receiving gene therapy.
    Hershfield MS, Chaffee S, Sorensen RU.
    Pediatr Res; 1993 Jan; 33(1 Suppl):S42-7; discussion S47-8. PubMed ID: 8433874
    [Abstract] [Full Text] [Related]

  • 5. Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement.
    Aiuti A, Vai S, Mortellaro A, Casorati G, Ficara F, Andolfi G, Ferrari G, Tabucchi A, Carlucci F, Ochs HD, Notarangelo LD, Roncarolo MG, Bordignon C.
    Nat Med; 2002 May; 8(5):423-5. PubMed ID: 11984564
    [No Abstract] [Full Text] [Related]

  • 6. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with CD34+ selected autologous peripheral blood cells transduced with a human ADA gene. Amendment to clinical research project, Project 90-C-195, January 10, 1992.
    Blaese RM, Culver KW, Chang L, Anderson WF, Mullen C, Nienhuis A, Carter C, Dunbar C, Leitman S, Berger M.
    Hum Gene Ther; 1993 Aug; 4(4):521-7. PubMed ID: 7691188
    [Abstract] [Full Text] [Related]

  • 7. Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID).
    Chan B, Wara D, Bastian J, Hershfield MS, Bohnsack J, Azen CG, Parkman R, Weinberg K, Kohn DB.
    Clin Immunol; 2005 Nov; 117(2):133-43. PubMed ID: 16112907
    [Abstract] [Full Text] [Related]

  • 8. IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency.
    Chaffee S, Mary A, Stiehm ER, Girault D, Fischer A, Hershfield MS.
    J Clin Invest; 1992 May; 89(5):1643-51. PubMed ID: 1569204
    [Abstract] [Full Text] [Related]

  • 9. Bone marrow transplantation and alternatives for adenosine deaminase deficiency.
    Gaspar HB.
    Immunol Allergy Clin North Am; 2010 May; 30(2):221-36. PubMed ID: 20493398
    [Abstract] [Full Text] [Related]

  • 10. A study on the inhibition of adenosine deaminase.
    Alunni S, Orrù M, Ottavi L.
    J Enzyme Inhib Med Chem; 2008 Apr; 23(2):182-9. PubMed ID: 18343902
    [Abstract] [Full Text] [Related]

  • 11. Reduced thymic output, increased spontaneous apoptosis and oligoclonal B cells in polyethylene glycol-adenosine deaminase-treated patients.
    Malacarne F, Benicchi T, Notarangelo LD, Mori L, Parolini S, Caimi L, Hershfield M, Notarangelo LD, Imberti L.
    Eur J Immunol; 2005 Nov; 35(11):3376-86. PubMed ID: 16276484
    [Abstract] [Full Text] [Related]

  • 12. Advances in gene therapy for ADA-deficient SCID.
    Aiuti A.
    Curr Opin Mol Ther; 2002 Oct; 4(5):515-22. PubMed ID: 12435054
    [Abstract] [Full Text] [Related]

  • 13. [Transplantation of genetically modified cells in the treatment of children with SCID: great hopes and recent disappointments].
    Smogorzewska EM, Weinberg KI, Kohn DB.
    Med Wieku Rozwoj; 2003 Oct; 7(1):27-34. PubMed ID: 13130167
    [Abstract] [Full Text] [Related]

  • 14. An adenosine deaminase (ADA) allele contains two newly identified deleterious mutations (Y97C and L106V) that interact to abolish enzyme activity.
    Jiang C, Hong R, Horowitz SD, Kong X, Hirschhorn R.
    Hum Mol Genet; 1997 Dec; 6(13):2271-8. PubMed ID: 9361033
    [Abstract] [Full Text] [Related]

  • 15. T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years.
    Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, Shearer G, Chang L, Chiang Y, Tolstoshev P, Greenblatt JJ, Rosenberg SA, Klein H, Berger M, Mullen CA, Ramsey WJ, Muul L, Morgan RA, Anderson WF.
    Science; 1995 Oct 20; 270(5235):475-80. PubMed ID: 7570001
    [Abstract] [Full Text] [Related]

  • 16. Twenty-Five Years of Gene Therapy for ADA-SCID: From Bubble Babies to an Approved Drug.
    Ferrua F, Aiuti A.
    Hum Gene Ther; 2017 Nov 20; 28(11):972-981. PubMed ID: 28847159
    [Abstract] [Full Text] [Related]

  • 17. Defective B cell tolerance in adenosine deaminase deficiency is corrected by gene therapy.
    Sauer AV, Morbach H, Brigida I, Ng YS, Aiuti A, Meffre E.
    J Clin Invest; 2012 Jun 20; 122(6):2141-52. PubMed ID: 22622038
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Function of murine adenosine deaminase in the gastrointestinal tract.
    Xu PA, Kellems RE.
    Biochem Biophys Res Commun; 2000 Mar 24; 269(3):749-57. PubMed ID: 10720488
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.